Micro-RNAs targeting the estrogen receptor alpha involved in endocrine therapy resistance in breast cancer

被引：0
|
作者：
Marquez-Mendoza, J. M. [2 ]
Baranda-Avila, N. [1 ]
Lizano, M. [1 ,3 ]
Langley, E. [1 ]
机构：
[1] Inst Nacl Cancerol, Unidad Invest Biomed Canc, Subdirecc Invest Bas, Mexico City 14080, Mexico
[2] Univ Nacl Autonoma Mexico, Programa Doctorado Ciencias Biomed, Inst Invest Biomed, Ciudad Univ, Mexico City 04510, Mexico
[3] Univ Nacl Autonoma Mexico, Dept Med Genom & Toxicol Ambiental, Inst Invest Biomed, Ciudad Univ, Mexico City 04510, Mexico
来源：
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE | 2025年 / 1871卷 / 05期
关键词：
Noncoding RNAs; micro-RNAs; Estrogen receptor alpha; Endocrine therapy resistance; Breast cancer; ENHANCES TAMOXIFEN RESISTANCE; ER-ALPHA; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; DIFFERENTIAL EXPRESSION; ANTIESTROGEN RESISTANCE; PROTEIN EXPRESSION; MIR-221; PROMOTES; DRUG-RESISTANCE; DOWN-REGULATION;
D O I：
10.1016/j.bbadis.2025.167783
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Endocrine therapy resistance (ETR) in breast cancer (BC) is a multicausal phenomenon with diverse alterations in the tumor cell interactome. Within these alterations, non-coding RNAs (ncRNAs) such as micro-RNAs (miRNAs) modulate the expression of tumor suppressor genes and proto-oncogenes, such as the ESR1 gene encoding estrogen receptor alpha (ER alpha). This work aims to review the effects of miRNAs targeting ER alpha mRNA and their mechanisms related to ETR in BC. A thorough review of the literature and an in silico study were carried out to elucidate the involvement of each miRNA, thus contributing to the understanding of ETR in BC.
引用
收藏
页数：17
相关论文
共 50 条
  • [21] Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications
    Campos-Parra, Alma D.
    Cuamani Mitznahuatl, Gerardo
    Pedroza-Torres, Abraham
    Vazquez Romo, Rafael
    Porras Reyes, Fany Iris
    Lopez-Urrutia, Eduardo
    Perez-Plasencia, Carlos
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (06)
  • [22] Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives
    Barone, Ines
    Caruso, Amanda
    Gelsomino, Luca
    Giordano, Cinzia
    Bonofiglio, Daniela
    Catalano, Stefania
    Ando, Sebastiano
    OBESITY REVIEWS, 2022, 23 (02)
  • [23] Molecular Mechanism and Clinical Implications of Endocrine Therapy Resistance in Breast Cancer
    Arpino, Grazia
    De Angelis, Carmine
    Giuliano, Mario
    Giordano, Antonio
    Falato, Claudette
    De Laurentiis, Michele
    De Placido, Sabino
    ONCOLOGY, 2009, 77 : 23 - 37
  • [24] Estrogen Receptor Alpha and its Ubiquitination in Breast Cancer Cells
    Tecalco-Cruz, Angeles C.
    Ramirez-Jarquin, Josue O.
    Cruz-Ramos, Eduardo
    CURRENT DRUG TARGETS, 2019, 20 (06) : 690 - 704
  • [25] The Central Contributions of Breast Cancer Stem Cells in Developing Resistance to Endocrine Therapy in Estrogen Receptor (ER)-Positive Breast Cancer
    Rodriguez, David
    Ramkairsingh, Marc
    Lin, Xiaozeng
    Kapoor, Anil
    Major, Pierre
    Tang, Damu
    CANCERS, 2019, 11 (07)
  • [26] Peptides Targeting Estrogen Receptor Alpha-Potential Applications for Breast Cancer Treatment
    Leclercq, Guy
    Gallo, Dominique
    Cossy, Janine
    Laios, Ioanna
    Larsimont, Denis
    Laurent, Guy
    Jacquot, Yves
    CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (25) : 2632 - 2653
  • [27] miR-205 Regulates Tamoxifen Resistance by Targeting Estrogen Receptor Coactivator MED1 in Human Breast Cancer
    Ouyang, Bin
    Bi, Mingjun
    Jadhao, Mahendra
    Bick, Gregory
    Zhang, Xiaoting
    CANCERS, 2024, 16 (23)
  • [28] Micro-RNAs: The new potential biomarkers in cancer diagnosis, prognosis and cancer therapy
    Mansoori, B.
    Mohammadi, A.
    Shirjang, S.
    Baradaran, B.
    CELLULAR AND MOLECULAR BIOLOGY, 2015, 61 (05) : 1 - 10
  • [29] Predicting resistance to endocrine therapy in breast cancer: It's time for epigenetic biomarkers
    Fontes-Sousa, Mario
    Amorim, Maria
    Salta, Sofia
    De Sousa, Susana Palma
    Henrique, Rui
    Jeronimo, Carmen
    ONCOLOGY REPORTS, 2019, 41 (03) : 1431 - 1438
  • [30] Impact of adding the multikinase inhibitor sorafenib to endocrine therapy in metastatic estrogen receptor-positive breast cancer
    Massarweh, Suleiman
    Moss, Jessica
    Wang, Chi
    Romond, Edward
    Slone, Stacey
    Weiss, Heidi
    Karabakhtsian, Rouzan G.
    Napier, Dana
    Black, Esther P.
    FUTURE ONCOLOGY, 2014, 10 (15) : 2435 - 2448
12345